Arca
Skip to content
Tools
Tools

EGLN2: Prolyl hydroxylase EGLN2

Prolyl hydroxylase that mediates hydroxylation of proline residues in target proteins, such as ATF4, IKBKB, CEP192 and HIF1A.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on EGLN2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Vadadustat

Phase 30

    Phase 21

    • Molidustat

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      VadadustatBoxed warningApprovedAkebia TherapeuticsSmall moleculeInhibitorHypoxia-inducible factor prolyl hydroxylase 1 inhibitor3
      MolidustatPhase 2BayerSmall moleculeInhibitorHypoxia-inducible factor prolyl hydroxylase 1 inhibitor1

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 4 in all, from ClinicalTrials.gov.

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Anemia
      0.60
      Chronic renal failure syndrome
      0.37
      Stage 5 chronic kidney disease
      0.33
      Neurodegenerative disease
      0.28
      Familial colorectal cancer
      0.27
      Kidney disorder
      0.26
      Smoking behavior
      0.18

      Genes and related targets

      Complexes and families that share a gene with this target
      Genes
      EGLN2

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3028, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q96KS0, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.